Skip to content
Illustration of changes in bone structure in osteoporosis

Osteoporosis Medicines and Dental Implants: Bisphosphonates and Denosumab

Contents

An osteoporosis diagnosis or treatment for bone loss does not mean that all dental care is impossible. For a procedure involving bone, such as implant placement, the disease and the effects of its medicines need separate consideration. Neither “my osteoporosis means an implant cannot integrate” nor “my dentist does not need to know about my injection” is a sound starting point. The decision brings together the medicine, its purpose, oral health and the proposed procedure.

The first practical step is important: do not stop osteoporosis medicine or postpone an injection on your own to prepare for an implant. These medicines are prescribed to reduce fractures. If dental treatment requires any change, the prescribing clinician and dentist should weigh the benefits and risks together and agree an individual plan. A fixed waiting period found online is not a safe personal prescription.

Osteoporosis and the amount of jawbone are different questions

Osteoporosis is a systemic condition associated with reduced bone strength and increased fracture risk. The height and width of bone at an implant site are local measurements. A bone-density scan of the hip or spine does not give the three-dimensional dimensions of that site. Equally, a dental CT scan does not replace medical assessment for osteoporosis. The amount and structure of jawbone are assessed alongside the oral examination.

An osteoporosis report therefore does not establish that implants are impossible or a graft is compulsory. Time since tooth loss, gum disease, local infection, the sinus or nerve canal and the planned replacement teeth also matter. Age, smoking and general health receive separate consideration. Assessing medicine-related risk adds to this local planning; it does not replace it.

Why does the dentist ask about bisphosphonates and denosumab?

Bisphosphonates and denosumab belong to a group of medicines that reduce bone breakdown, called antiresorptives. Alendronate, risedronate, ibandronate and zoledronic acid are bisphosphonate examples; denosumab is a different active ingredient. Whether treatment is a tablet, an intravenous infusion or an injection under the skin is recorded, but the route alone cannot establish the whole risk. The same substance may be used at different doses and frequencies for different conditions.

Certain medicines are associated with a rare but important complication called medication-related osteonecrosis of the jaw, or MRONJ. It involves impaired healing and loss of vitality in an area of jawbone. It may follow an extraction or bone surgery, but can also arise without a procedure. Osteoporosis medicines are not all alike. A photograph of the packaging or prescription is more useful than saying only that you have “a bone injection”.

Osteoporosis treatment must be distinguished from cancer treatment

The risk of jaw osteonecrosis with osteoporosis regimens is generally low, but not zero. More intensive, high-dose antiresorptive treatment used for certain cancers affecting bone carries a higher risk. Applying one internet percentage to both groups is misleading. Dose, frequency, total exposure, accompanying steroids or cancer medicines, oral inflammation and the extent of surgery can affect the assessment.

New implant placement is generally considered inappropriate during high-dose antiresorptive treatment for cancer; the oncology and relevant oral surgery teams need to assess the situation. For a person receiving these medicines for osteoporosis, implants are not automatically ruled out. The implant option can be discussed alongside personal risk and alternatives. Evidence, particularly about long-term outcomes, has limitations. The same promise of success or freedom from complications cannot be made to everyone.

What information should you bring?

An up-to-date medicines list should include the active ingredient and brand, dose, route, reason for treatment, starting date, last dose and planned next dose. Include bone medicines taken in the past. Bisphosphonates, in particular, can remain in bone long after treatment stops; saying “I no longer take it” does not make the history irrelevant. The prescriber’s details and available medical reports make coordination easier.

Also report a previous non-healing jaw wound or osteonecrosis, difficult healing after extraction, head and neck radiotherapy, diabetes, smoking and other medicines. Mention existing implants. Starting a new bone medicine does not automatically require their removal; the mouth and tissues around them should be assessed and maintenance planned. A previous extraction that healed normally also does not prove that every future procedure will be risk-free.

Will a drug holiday or blood test solve the problem?

A temporary interruption, often called a drug holiday, is not a proven, compulsory precaution for everyone. Its effectiveness in reducing jaw risk remains uncertain. Briefly stopping a bisphosphonate does not demonstrate that the risk has disappeared. With denosumab, delaying a dose or stopping without a plan can increase the risk of vertebral fractures in some people. The injection schedule and timing of surgery must not be changed without agreement from the relevant clinicians.

An individual timing or medicine plan may be appropriate, but do not construct your own schedule from this article. A blood test of bone turnover, such as CTX, cannot by itself certify that an implant is safe: no validated safe threshold reliably predicts jaw osteonecrosis. Other tests may be needed for general health, but their results do not replace clinical assessment and an informed decision.

Improving oral health and comparing the options

A dental examination checks decay, gum inflammation, infection around root tips and areas rubbed by dentures. Leaving infection untreated simply because a person takes these medicines is inappropriate. Where a tooth can be retained, root canal treatment or a restoration may be considered before extraction. Necessary treatment of a tooth that cannot be saved should not be delayed solely through fear; an appropriate risk-based surgical and follow-up plan is needed. Urgent infection is a separate issue from an elective implant.

If bone treatment is due to start, arranging dental assessment beforehand where possible is useful, particularly when intensive cancer treatment requires team coordination. Do not independently delay important medical treatment to do this. Discuss the benefits, limitations and cleaning needs of alternatives such as a bridge or removable denture. Do not start antibiotics or a mouthwash yourself merely because you take a bone medicine; any prescription depends on the procedure and findings.

Which symptoms need review after treatment?

If an implant is chosen, healing checks and long-term maintenance should be planned. Seek review for bleeding gums, denture rubbing, new discomfort around an implant or difficulty cleaning. Good hygiene and regular care help reduce risk, but cannot remove it entirely. Problems are not confined to the period immediately after surgery. Changes in medicines and medical conditions also need to be recorded at follow-up visits.

Contact the dentist promptly for a non-healing mouth wound, exposed bone, discharge, swelling, unexplained loose teeth, new numbness or persistent jaw pain. Do not wait to reach the eight-week interval you may have read about in a diagnostic definition; these symptoms can also have other causes. Rapidly increasing facial or neck swelling, difficulty swallowing or breathing requires emergency assessment. Do not change your medicine dose while waiting to be examined.

Frequently asked questions

Does osteoporosis mean an implant will definitely fail?

No. Osteoporosis alone does not establish that an implant will fail. The local bone, oral health, general condition and medicines are assessed together. A decision follows discussion of personal risk and alternatives; success cannot be guaranteed.

Do tablets and bone injections carry the same risk?

Tablet versus injection is not a sufficient classification. The active ingredient, dose, frequency, purpose and duration matter. Osteoporosis treatment and intensive high-dose regimens used for certain cancers are assessed separately. Show the packaging or prescription to your dentist.

Should I stop my bisphosphonate before an implant?

Do not stop it on your own. A short interruption does not establish that risk has disappeared and may affect fracture protection. Whether any interruption is appropriate depends on an individual benefit–risk assessment by the dentist and prescriber. There is no shared interval for everyone.

Can I delay my denosumab injection for dental treatment?

Do not make this change yourself. Unplanned interruption or delay can increase vertebral fracture risk. If necessary, the relevant clinicians should coordinate surgery and the medicine schedule. An interval described online is not an individual instruction.

Does a normal CTX result mean there is no jaw osteonecrosis risk?

No. CTX or any single blood test cannot guarantee that jaw osteonecrosis will not occur. It is not a validated safe-implant threshold. Medicine history, the oral examination, infection and the extent of the proposed procedure must be assessed together.

What should I do if an extraction site is not healing while I take these medicines?

Contact your dentist promptly, particularly if there is exposed bone, discharge, swelling, numbness or continuing pain. Do not wait for a diagnostic time threshold. Rapidly spreading swelling or trouble swallowing or breathing is an emergency. Do not stop your medicine yourself.

Image: Servier Medical Art · CC BY-SA 3.0. Proportionally resized and converted to WebP.

Appointment line

+90 551 507 36 46

Request an appointment

Leave your name and number. We will call to arrange your appointment.

Message us on WhatsApp